FIELD: medicine.
SUBSTANCE: suppositories, containing uniformly distributed in one suppository recombinant human interferon-alpha-2b in an amount of 400000-600000 IU and immunoglobulins IgA, IgM and IgG in an amount of 0.1-0.3 g, are additionally rectally introduced as the second medication to an adult patient in case of the long-term introduction of an opioid-containing medication. The dose constitutes 2-3 suppositories 2-3 times per day with the reduction of the daily dose by 1-3 suppositories in case of the reduction of pain sensation to 2-3 points by a ten-point scale and expressed sedation. If pain sensation increases to 6-8 points by the ten-point visual analogue scale, the daily dose is increased by 1-3 suppositories.
EFFECT: application of the claimed method makes it possible to ensure the prevention of the opioid dose increase and an increase of the level of antibodies to interferon-alpha in the patients' blood serum in case of the long-term application of opioids.
5 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS WITH INFECTIOUS DISEASES | 1999 |
|
RU2146531C1 |
ANTIVIRAL AND ANTIMICROBIAL ORAL COMPOSITION | 2008 |
|
RU2457856C2 |
METHOD OF PREPARING IMMUNOGLOBULIN PREPARATION CONTAINING RECOMBINANT ALPHA-2-INTERFERON | 1997 |
|
RU2116083C1 |
ANTIVIRAL AND ANTIMICROBIAL COMPOSITION | 2008 |
|
RU2457857C2 |
METHOD OF TRICHOMONIASIS TREATMENT | 1997 |
|
RU2114634C1 |
BIOLOGICALLY ACTIVE ADDITION | 2000 |
|
RU2164765C1 |
FOOD BIOLOGICALLY ACTIVE ADDITION | 1999 |
|
RU2144294C1 |
ANTIVIRAL AND ANTIMICROBIAL COMPOSITION | 2008 |
|
RU2457855C2 |
COMPOSITION ELICITING ANTIVIRAL EFFECT | 2004 |
|
RU2247576C1 |
COMPLEX ACTION MEDICATION AND METHOD OF ITS PRODUCTION | 2012 |
|
RU2519553C1 |
Authors
Dates
2015-04-10—Published
2014-02-14—Filed